PTN News

  • PTN lisinopril study enrolls first participant June 25, 2012 Principal investigator Daniel Feig, MD, PhD, of University of Alabama-Birmingham has successfully enrolled the first participant into the PTN study of lisinopril use for the control of high blood pressure in kids with kidney transplants. Seven sites are currently recruiting participants into this study: Arkansas Children’s Hospital in Little Rock, Cincinnati Children’s Hospital, Children’s Mercy Hospital ...
  • PTN hydroxyurea trial prepares for interim analysis June 22, 2012 The PTN hydroxyurea trial enrolled its 7th and 8th patients on June 12 and 14, 2012, thanks to the collective efforts of Nancy Green, MD, of Columbia University Medical Center, Robert Liem, MD, of Children’s Memorial Hospital in Chicago, and Courtney Thornburg, MD, of Duke University Medical Center. Enrollment into this trial is proceeding in two ...
  • The PTN lisinopril study is now looking for participants to enroll at four active sites May 17, 2012 Four sites are now actively seeking participants to enroll into the PTN study of lisinopril for the control of high blood pressure in kids with kidney transplants: University of Alabama–Birmingham, Arkansas Children’s Hospital in Little Rock, University of Michigan at Ann Arbor, and New York University Langone Medical Center. Lisinopril is a drug used in children ...
  • The PTN lisinopril study nears the start of enrollment April 17, 2012 The PTN study of the safety and pharmacokinetics of lisinopril in pediatric kidney transplant recipients will begin enrolling patients at the end of April. At that time, 4 of the anticipated 8 sites should be activated. Lisinopril use is FDA-approved in children aged 6+ years for the treatment of high blood pressure, a condition that is ...
  • The PTN Mercy Method tape study completes enrollment April 6, 2012 The PTN’s Mercy Method™ tape study has successfully completed enrollment of 625 evaluable patients. Trial enrollment was concluded in less than two months. The study team attributes this impressive enrollment rate to the efforts of lead investigator Susan Abdel-Rahman, PharmD, of Children’s Mercy Hospitals and Clinics in Kansas City, Missouri; principal investigators Ian Paul, MD, of ...
  • StaR Child Summit 2012 March 30, 2012
  • Enrollment grows in the PTN hydroxyurea study March 27, 2012 The PTN’s hydroxyurea (HU) study is kicking into high gear, with sites reportedly expecting an influx of at least 5 newly enrolled patients over the upcoming spring holiday. Hydroxyurea is the only major drug breakthrough for the treatment of sickle cell disease within the past 20 years. Although it is approved by the Food and Drug ...
  • PTN investigator Kelly Wade talks about why research matters and patient safeguards in clinical research March 16, 2012 Why is it important that we do research in infants and children? The only way to safely dose medicine for children is to study the medicine in children. When it comes to how the body handles a medication, we have to remember that children are not small adults and infants are not even small children. Fortunately, ...
  • The PTN lisinopril study to begin enrolling patients in April 2012 March 9, 2012 A study to determine the safety and pharmacokinetics of lisinopril in children and adolescents receiving kidney transplants will begin enrolling participants in April 2012. Lisinopril is approved by the U.S. Food and Drug Administration for the treatment of children aged 6 years and older and adults with high blood pressure, heart failure, and heart attack. High ...
  • First patient enrolled in hydroxyurea study February 13, 2012 Breaking news announcement On January 27, 2012, the first patient was successfully enrolled into the PTN’s hydroxyurea (HU) study. Hydroxyurea is the only major drug breakthrough for the treatment of sickle cell disease within the past 20 years. It is the only drug approved by the FDA to treat adults with sickle cell anemia, and so it ...